Gemtuzumab ozogamicin | Interleukin Related interleukin-related.com

Product Name :
Gemtuzumab ozogamicin

Search keywords :
CD33

drugId :
null

Target Vo:
Myeloid cell surface antigen CD33

Target Vo Short Name :
CD33

Moa_Name:
DNA inhibitors

First Approval Country :
Japan

First Approval Date Filter:
2008

Origin Company_Name :
Pfizer Inc

Active Company_Name :
Columbia University

Active Indication_Name:
Leukemia, Myeloid, Acute

In Active Indication_Name:
Leukemia, Lymphocytic, Chronic, B-Cell

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
MMAE Antibody (YA899) Purity
Cyclin D1 Rabbit mAb Epigenetic Reader Domain
RAB7 Antibody: RAB7 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 23 kDa, targeting to RAB7. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts